NATIONAL BREAST CANCER FOUNDATION (NBCF) OUTLINES PINK HORIZON RESEARCH STRATEGY AT BREAST CANCER FORUM Breast Cancer Awareness Month demonstrates integral role of NBCF in research and clinical support
Filmed in Brisbane, Queensland | November 2024
Associate Professor Cleola Anderiesz, Chief Executive Officer of the National Breast Cancer Foundation, leads an organisation dedicated to funding world-class breast cancer research in Australia. The Foundation has a bold vision of achieving zero deaths from breast cancer.
Every October, during Breast Cancer Awareness Month, the foundation uses this time to raise awareness about breast cancer and its impact in Australia. It also emphasises the critical need for funding breast cancer research to improve outcomes.
The National Breast Cancer Foundation collaborates with researchers, providing essential funding while also engaging them, clinicians, and consumers to establish research priorities.
Australian Health Journal met with Assoc Prof Anderiesz to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer.
Recently, Assoc Professor Anderiesz presented at the Public Breast Cancer Research Forum hosted by The University of Queensland and the Translational Research Institute, where she highlighted the accomplishments of the National Breast Cancer Foundation over the past 30 years. During this time, the Foundation has invested over $200 million into more than 600 research projects across Australia, supporting 1,800 researchers at 120 institutes to advance impactful breast cancer research.
Professor Anderiesz believes it is essential for all members of the breast cancer community to consistently seek opportunities to raise awareness about the disease’s impact. This awareness should extend beyond October and include efforts to inform primary care physicians and specialists. Additionally, there is a need to promote groundbreaking research and advocate for changes in policy and care to improve outcomes for individuals affected by breast cancer.
You Might also like
-
Developing the nation’s first Health and Medical Research Strategy
Professor Steve Wesselingh serves as the CEO of NHMRC, having initially trained as an infectious diseases doctor. His career includes prominent roles such as Head of the Infectious Diseases Unit at the Alfred Hospital, Director of the Burnett, Dean of Medicine at Monash University, and the inaugural Director of SAHMRI. Under his leadership, NHMRC plays a critical role in funding health and medical research, allocating approximately a billion dollars annually to investigator-led projects, clinical trials, and various strategic initiatives. NHMRC also collaborates internationally with organisations such as the MRC and the EU, and manages grant allocation for the MRFF, which distributes $650 million each year.
-
Impact of genetic pathologist role across medicine
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
-
Gavin Fox-Smith talks Medical Technology
Former Johnson & Johnson ANZ Managing Director, Gavin Fox-Smith on working in large & small MedTech companies